Cat No. 35-D62

Abiraterone

2 mg

For research purposes only

Abiraterone is a potent steroidal inhibitor of cytochrome P450 CYP17 with an IC50 at 4 nM. It is currently undergoing a Phase II clinical trial as a potent treatment for prostate cancer. In preclinical trials, Abiraterone has been shown to selectively inhibit the target enzyme, resulting in inhibition of testosterone production in both the adrenals and the testes. In addition, another clinical trial is in process for the use of Abiraterone as a treatment for breast cancer.

TECHNICAL INFORMATION



Other Names: CB-7598, CB7598

Chemical Formula: $C_{24}H_{31}NO$

CAS Number: 154229-19-3

Molecular Weight: 349.51

Purity: >98%

Appearance: a crystalline solid

Solubility: DMSO

STORAGE AND HANDLING

Storage: Store at 4°C and protected from light. Following reconstitution, store aliquots at -20°C.

Stability: Stock solutions stable at -20°C for up to 2 years.

Shipping Conditions: Shipped at room temperature.

PRODUCT USE

Soluble in DMSO. For a 10mM concentrated stock solution, add 572 µl to the entire contents of the vial. If precipitate is observed, vortex for 5 minutes. For most cells, the maximum tolerance to DMSO is less than 0.5%.

REFERENCES

1. Jarman et al. (1998) The 16,17-double bond is needed for irreversible inhibition of human cytochrome p45017alpha by abiraterone (17-(3-pyridyl)androsta-5, 16-dien-3beta-ol) and related steroidal inhibitors. J Med Chem. 41(27):5375-81.
2. Attard et al. (2009) Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer. J Clin Oncol. 27(23):3742-8.
3. Danila et al. (2010) Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancer. J Clin Oncol. 28 (9):1496-501.